CN109963873B - 新颖抗cd137抗体和其用途 - Google Patents

新颖抗cd137抗体和其用途 Download PDF

Info

Publication number
CN109963873B
CN109963873B CN201780071444.6A CN201780071444A CN109963873B CN 109963873 B CN109963873 B CN 109963873B CN 201780071444 A CN201780071444 A CN 201780071444A CN 109963873 B CN109963873 B CN 109963873B
Authority
CN
China
Prior art keywords
antibody
antigen
binding fragment
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780071444.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN109963873A (zh
Inventor
P·埃尔马克
S·弗里策尔
C·费罗瑞因
J·彼得森
A·萨尔
K·E·史密斯
L·瓦拉斯
L·冯尚茨
N·韦通迈基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alligator Bioscience AB
Original Assignee
Alligator Bioscience AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alligator Bioscience AB filed Critical Alligator Bioscience AB
Publication of CN109963873A publication Critical patent/CN109963873A/zh
Application granted granted Critical
Publication of CN109963873B publication Critical patent/CN109963873B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780071444.6A 2016-11-21 2017-11-21 新颖抗cd137抗体和其用途 Active CN109963873B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1619648.7A GB201619648D0 (en) 2016-11-21 2016-11-21 Novel antibodies and uses thereof
GB1619648.7 2016-11-21
PCT/EP2017/079930 WO2018091740A2 (en) 2016-11-21 2017-11-21 Novel antibodies and uses thereof

Publications (2)

Publication Number Publication Date
CN109963873A CN109963873A (zh) 2019-07-02
CN109963873B true CN109963873B (zh) 2023-12-26

Family

ID=57993708

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780071444.6A Active CN109963873B (zh) 2016-11-21 2017-11-21 新颖抗cd137抗体和其用途

Country Status (14)

Country Link
US (3) US11535678B2 (cg-RX-API-DMAC7.html)
EP (1) EP3541844A2 (cg-RX-API-DMAC7.html)
JP (1) JP7068303B2 (cg-RX-API-DMAC7.html)
KR (1) KR102679632B1 (cg-RX-API-DMAC7.html)
CN (1) CN109963873B (cg-RX-API-DMAC7.html)
AU (1) AU2017360094B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019010265A2 (cg-RX-API-DMAC7.html)
CA (1) CA3044339A1 (cg-RX-API-DMAC7.html)
GB (1) GB201619648D0 (cg-RX-API-DMAC7.html)
IL (1) IL266738B2 (cg-RX-API-DMAC7.html)
MX (1) MX2019005911A (cg-RX-API-DMAC7.html)
NZ (1) NZ754051A (cg-RX-API-DMAC7.html)
RU (1) RU2019116624A (cg-RX-API-DMAC7.html)
WO (1) WO2018091740A2 (cg-RX-API-DMAC7.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201811184UA (en) 2016-06-20 2019-01-30 F Star Beta Ltd Lag -3 binding members
US10174122B2 (en) * 2017-01-06 2019-01-08 Eutilex Co., Ltd. Anti-human 4-1BB antibodies and uses thereof
BR112019017241A2 (pt) 2017-04-13 2020-04-14 Agenus Inc. anticorpos anti-cd137 e métodos de uso dos mesmos
CR20200042A (es) * 2017-08-01 2020-03-03 Lilly Co Eli Anticuerpos anti-cd137
US11512134B2 (en) 2017-08-01 2022-11-29 Eli Lilly And Company Anti-CD137 antibodies
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
CN112020517B (zh) 2018-03-23 2024-10-29 伊莱利利公司 用于与抗pd-l1抗体组合的抗cd137抗体
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
AU2019301206B2 (en) 2018-07-12 2025-10-30 Invox Pharma Limited Antibody molecules that bind CD137 and OX40
GB201811408D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811404D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
BR112021000394A2 (pt) 2018-07-12 2021-04-06 F-Star Beta Limited Moléculas de anticorpo que se ligam a pd-l1 e cd137
JP7598312B2 (ja) 2018-07-23 2024-12-11 ハイデルベルク ファーマ リサーチ ゲーエムベーハー 同種異系の細胞療法における抗－ｃｄ１３７抗体薬物コンジュゲート（ａｄｃ）の使用
MX2021001431A (es) * 2018-08-10 2021-05-12 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso.
CN112739718B (zh) * 2018-09-12 2024-11-26 祐和医药科技(北京)有限公司 抗tnfrsf9抗体及其用途
US12227582B2 (en) 2019-01-02 2025-02-18 Qlsf Biotherapeutics Inc. CD137 agonist antibodies and uses thereof
WO2020216947A1 (en) 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
BR112021026309A2 (pt) 2019-06-26 2022-06-07 Ap Biosciences Inc Anticorpos para ativação de células t
KR20220087479A (ko) * 2019-11-13 2022-06-24 허페이 한커맵 바이오테크놀로지 컴퍼니 리미티드 인간 4-1bb와 결합할 수 있는 분자 및 이의 응용
MX2022008412A (es) 2020-01-07 2022-08-08 Univ Texas Variantes de enzima que agotan metiltioadenosina/adenosina mejorada humana para terapia de cancer.
KR20220132555A (ko) 2020-01-29 2022-09-30 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Nrg1 융합체를 사용한 암 치료를 위한 egfr/her2 티로신 키나제 억제제 및/또는 her2/her3 항체의 사용
KR20220133238A (ko) 2020-01-29 2022-10-04 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Nrg1 융합체가 있는 암의 치료를 위한 포지오티닙의 용도
JP7715722B2 (ja) * 2020-02-28 2025-07-30 上海復宏漢霖生物技術股▲フン▼有限公司 抗ｃｄ１３７コンストラクト及びその使用
JP2023504675A (ja) 2020-05-19 2023-02-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ガンの処置のための結合分子
CN113842456B (zh) * 2020-06-28 2022-07-26 上海齐鲁制药研究中心有限公司 一种抗人4-1bb的单克隆抗体制剂及其用途
WO2022002063A1 (zh) * 2020-06-30 2022-01-06 和铂医药(上海)有限责任公司 一种4-1bb结合蛋白及其应用
KR20230129484A (ko) * 2021-01-08 2023-09-08 베이징 한미 파마슈티컬 컴퍼니 리미티드 4-1bb와 특이적으로 결합하는 항체 및 그 항원 결합단편
JP2024522234A (ja) 2021-06-18 2024-06-11 アリゲーター・バイオサイエンス・アーベー 新規な併用療法及びその使用
US20250084155A1 (en) 2021-09-29 2025-03-13 Board Of Regents, The University Of Texas System Anti-hsp70 antibodies and therapeutic uses thereof
WO2023126821A1 (en) * 2021-12-29 2023-07-06 Curateq Biologics Private Limited C1q binding assay
GB202210965D0 (en) 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages
GB202210957D0 (en) 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
EP4789724A2 (en) * 2022-09-22 2026-08-12 ABlink Biotech Co., Ltd. Anti-4-1bb nanobody 137-7, preparation therefor, and use thereof
CN116041517B (zh) * 2022-12-19 2025-02-25 首都医科大学附属北京胸科医院 一种抗人cd137抗体及其应用
CN116162162B (zh) * 2022-12-19 2025-05-27 首都医科大学附属北京胸科医院 一种大鼠抗小鼠cd137抗体或其功能性片段、工具抗体及其应用
CN116271009A (zh) * 2023-01-13 2023-06-23 深圳市乐土生物医药有限公司 含有CpG佐剂和4-1BB抗体的药物组合物及其用途
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1867585A (zh) * 2003-10-10 2006-11-22 布里斯托尔-迈尔斯·斯奎布公司 抗人4－1bb(cd137)的完全人抗体
WO2016029073A2 (en) * 2014-08-22 2016-02-25 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
WO2016134358A1 (en) * 2015-02-22 2016-08-25 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd137

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
TWI423814B (zh) 2006-09-01 2014-01-21 Genticel 用於引發特異性細胞毒性ｔ淋巴細胞（ｃｔｌ）反應之組成物，包含一淋巴去除性化合物以及一含有抗原序列且以專業化抗原呈現細胞為標靶之分子
BR112017024770A2 (pt) * 2015-05-21 2018-07-31 Alligator Bioscience Ab polipeptídeos inovadores

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1867585A (zh) * 2003-10-10 2006-11-22 布里斯托尔-迈尔斯·斯奎布公司 抗人4－1bb(cd137)的完全人抗体
WO2016029073A2 (en) * 2014-08-22 2016-02-25 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
WO2016134358A1 (en) * 2015-02-22 2016-08-25 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd137

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody;Neil H. Segal et al;《Clin Cancer Res.》;20161018;第1929-1936页 *

Also Published As

Publication number Publication date
US20190352414A1 (en) 2019-11-21
GB201619648D0 (en) 2017-01-04
KR20190086691A (ko) 2019-07-23
US11535678B2 (en) 2022-12-27
AU2017360094B2 (en) 2024-12-12
IL266738B1 (en) 2024-02-01
US12509526B2 (en) 2025-12-30
WO2018091740A2 (en) 2018-05-24
NZ754051A (en) 2023-05-26
IL266738B2 (en) 2024-06-01
RU2019116624A (ru) 2020-12-21
US10689454B2 (en) 2020-06-23
BR112019010265A2 (pt) 2019-09-17
US20190352411A1 (en) 2019-11-21
WO2018091740A3 (en) 2018-06-28
US20230295325A1 (en) 2023-09-21
MX2019005911A (es) 2019-07-08
JP2020501531A (ja) 2020-01-23
AU2017360094A1 (en) 2019-06-20
EP3541844A2 (en) 2019-09-25
KR102679632B1 (ko) 2024-06-28
IL266738A (en) 2019-07-31
JP7068303B2 (ja) 2022-05-16
RU2019116624A3 (cg-RX-API-DMAC7.html) 2021-01-29
CA3044339A1 (en) 2018-05-24
CN109963873A (zh) 2019-07-02

Similar Documents

Publication Publication Date Title
US12509526B2 (en) Anti-CD137 antibodies and uses thereof
US12173082B2 (en) Bispecific polypeptides against CD137
EP3193926B1 (en) Novel antibodies and uses thereof
WO2020127376A2 (en) Novel polypeptides
JP2024515879A (ja) 抗ｓｉｇｌｅｃ組成物及びその使用
KR20230156727A (ko) 항-vsig4 항체 또는 이의 항원 결합 단편 및 용도
WO2024231251A1 (en) Anti-il1rap antibodies
JP2024522234A (ja) 新規な併用療法及びその使用
RU2826236C1 (ru) Антитело против vsig4 или его антигенсвязывающий фрагмент и их применение
WO2024023120A1 (en) Novel dosages of anti-cd137 antibody
WO2024023118A1 (en) Novel dosages of anti-cd137 antibody
CN122029197A (zh) 抗ctla-4抗体和相关结合分子及其方法和用途
EA049996B1 (ru) Антитело к siglec-10 (варианты)
HK40003232A (en) Novel bispecific polypeptides against cd137
HK40004686B (en) Novel bispecific polypeptides against cd137

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20380326

TG01 Patent term adjustment